References
1. First National TB Prevalence Survey 2018. Pretoria, South Africa: National Department of Health, South Africa, 2021. 2. Global TB Report. Geneva: World Health Organisation, , 2020. 3. Mortality and causes of death in South Africa, 2016: Findings from death notification. . Pretoria, South Africa: Statistics SA., 2018. 4. WHO High-Level Event galvanizes commitment and action to accelerate the gl
1. First National TB Prevalence Survey 2018. Pretoria, South Africa: National Department of Health, South Africa, 2021.
2. Global TB Report. Geneva: World Health Organisation, , 2020.
3. Mortality and causes of death in South Africa, 2016: Findings from death notification. . Pretoria, South Africa: Statistics SA., 2018.
4. WHO High-Level Event galvanizes commitment and action to accelerate the global drive to scale up TB prevention. 2021. https://www.who.int/news/item/16-06-2021-who-high-level-event-galvanizescommitment-and-action-to-accelerate-the-global-drive-to-scale-up-tb-prevention.
5. Shah M, Kasambira TS, Adrian PV, Madhi SA, Martinson NA, Dorman SE. Longitudinal analysis of QuantiFERON-TB Gold In-Tube in children with adult household tuberculosis contact in South Africa: a prospective cohort study. PLoS One 2011; 6(10): e26787.
6. Van Rie A, McCarthy K, Scott L, Dow A, Venter WD, Stevens WS. Prevalence, risk factors and risk perception of tuberculosis infection among medical students and healthcare workers in Johannesburg, South Africa. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2013; 103(11): 853-7.
7. Hanifa Y, Grant AD, Lewis J, Corbett EL, Fielding K, Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2009; 13(1): 39-46.
8. Mahomed H, Hawkridge T, Verver S, et al. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2011; 15(3): 331-6.
9. Wood R, Liang H, Wu H, et al. Changing prevalence of tuberculosis infection with increasing age in highburden townships in South Africa. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2010; 14(4): 406-12.
10. Middelkoop K, Bekker LG, Myer L, Dawson R, Wood R. Rates of tuberculosis transmission to children and adolescents in a community with a high prevalence of HIV infection among adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 47(3): 349-55.
11. Basera TJ, Ncayiyana J, Engel ME. Prevalence and risk factors of latent tuberculosis infection in Africa: a systematic review and meta-analysis protocol. BMJ open 2017; 7(7): e012636.
12. National Department of Health. South Africa’s National Strategic Plan for HIV,TB and STIs 2017 - 2022. Pretoria, South Africa: National Department of Health, 2017. http://sanac.org.za/wp-content/ uploads/2017/05/NSP_FullDocument_FINAL.pdf. (Accessed 15 February, 2018).
13. Uplekar M, Weil D, Lonnroth K, et al. WHO’s new end TB strategy. Lancet (London, England) 2015; 385(9979): 1799-801.
14. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; (1): CD000171.
15. De Jager P, Churchyard GJ, Ismail N, Kyaw KKK, Murray J, Nshuti L. Clinical guidelines on isoniazid preventive therapy for patients with silicosis in South Africa. Occup Health South Africa 2014; 20(11).
16. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. The New England journal of medicine 2011; 365(23): 2155-66.
17. Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. American journal of preventive medicine 2018; 55(2): 244-52.
18. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007; 45(6): 715-22.
19. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet (London, England) 1999; 353(9167): 1843-7.
20. WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. Geneva, Switzerland: World Health Organisation,, 2021.
21. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
22. Multi-drug resistant tuberculosis: A policy framweork on decentralised and deinstitutionalised management for South Africa Pretoria, South Africa: Department of Health, 2019.